| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S12282-011-0296-Z |
| P698 | PubMed publication ID | 21863310 |
| P50 | author | Shigehira Saji | Q88034326 |
| P2093 | author name string | Yasutsuna Sasaki | |
| Mark Pegram | |||
| Kazuhiro Araki | |||
| Michelle Gallas | |||
| P2860 | cites work | Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial | Q43241014 |
| Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer | Q43250044 | ||
| Should all patients with node-negative breast cancer receive adjuvant therapy? Identifying additional subsets of low-risk patients who are highly curable by surgery alone | Q43651478 | ||
| Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer | Q44279198 | ||
| HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. | Q44450066 | ||
| The full potential of breast cancer screening use to reduce mortality has not yet been realized in the United States. | Q44911276 | ||
| Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer | Q45287928 | ||
| Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients | Q46464385 | ||
| Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial | Q46736552 | ||
| Minimal and small size invasive breast cancer with no axillary lymph node involvement: the need for tailored adjuvant therapies | Q47402211 | ||
| Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy | Q47587986 | ||
| Trastuzumab treatment in t1ab, node-negative, human epidermal growth factor receptor 2-overexpressing breast carcinomas | Q48111542 | ||
| 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. | Q53243856 | ||
| Global cancer statistics | Q22241238 | ||
| Humanization of an anti-p185HER2 antibody for human cancer therapy | Q24561842 | ||
| High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller | Q24641848 | ||
| Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications | Q27860709 | ||
| Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers | Q28375856 | ||
| Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer | Q29547699 | ||
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| Cancer Incidence and Incidence Rates in Japan in 2005: Based on Data from 12 Population-based Cancer Registries in the Monitoring of Cancer Incidence in Japan (MCIJ) Project | Q33685238 | ||
| St. Gallen 2011: Summary of the Consensus Discussion | Q34189116 | ||
| Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer | Q34496969 | ||
| Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. The International (Ludwig) Breast Cancer Study Group | Q36032127 | ||
| Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literature | Q36464108 | ||
| HER2-positive breast cancer: current and future treatment strategies | Q36839672 | ||
| Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours. | Q37123529 | ||
| Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. | Q37523202 | ||
| Late mortality from pT1N0M0 breast carcinoma | Q39507969 | ||
| Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers | Q40321985 | ||
| Medical audit after 26,711 breast imaging studies: improved rate of detection of small breast carcinomas (classified as Tis or T1a,b) | Q42689079 | ||
| Upregulation of IKKalpha/IKKbeta by integrin-linked kinase is required for HER2/neu-induced NF-kappaB antiapoptotic pathway | Q42830760 | ||
| P433 | issue | 2 | |
| P921 | main subject | overexpression | Q61643320 |
| P304 | page(s) | 95-103 | |
| P577 | publication date | 2011-08-24 | |
| P1433 | published in | Breast Cancer | Q15752871 |
| P1476 | title | Possible available treatment option for early stage, small, node-negative, and HER2-overexpressing breast cancer | |
| P478 | volume | 19 |
| Q37595263 | HER2 overexpression a major risk factor for recurrence in pT1a-bN0M0 breast cancer: results from a French regional cohort. | cites work | P2860 |
Search more.